Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 6/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL907254 | 0.98 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Pyridine SCHEMBL7422031 | 0.96 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Pyridine SCHEMBL618965 | 0.90 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Benzene SCHEMBL6273750 | 0.90 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Pyridine SCHEMBL9766208 | 0.88 | NAPRT (0.41) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Pyridine SCHEMBL10539991 | 0.88 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Pyridine SCHEMBL1460187 | 0.88 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Pyridine SCHEMBL12476946 | 0.88 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Pyridine SCHEMBL1079036 | 0.86 | NAPRT (0.43) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT | |
| Pyridine SCHEMBL11779483 | 0.86 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2L3MBTL1TSHRNAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919941-B2 | Functional lipid constructs | KODE BIOTECH LIMITED (NZ) | 2021-02-16 | — | — | US | disclosed |
| US-10858384-B2 | Synthetic molecule constructs | KODE BIOTECH LIMITED (NZ) | 2020-12-08 | — | — | US | disclosed |
| US-20200123188-A1 | SYNTHETIC MOLECULE CONSTRUCTS | KODE BIOTECH LIMITED (NZ) | 2020-04-23 | — | — | US | disclosed |
| US-10414786-B2 | Synthetic membrane anchors | KODE BIOTECH LIMITED (NZ) | 2019-09-17 | — | — | US | disclosed |
| US-20180057518-A1 | SYNTHETIC MEMBRANE ANCHORS | KODE BIOTECH LTD. (NZ) | 2018-03-01 | — | — | US | disclosed |
| US-20170218027-A1 | FUNCTIONAL LIPID CONSTRUCTS | KODE BIOTECH LIMITED (NZ) | 2017-08-03 | — | — | US | disclosed |
| US-20160361423-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LTD (NZ) | 2016-12-15 | — | — | US | disclosed |
| US-9226968-B2 | Carbohydrate-lipid constructs and their use in preventing or treating viral infection | KODE BIOTECH LIMITED (NZ) | 2016-01-05 | — | — | US | disclosed |
| US-20140200191-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LIMITED (NZ) | 2014-07-17 | — | — | US | disclosed |
| US-20120277172-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LIMITED (NZ) | 2012-11-01 | — | — | US | disclosed |
| US-6706497-B2 | GENERATION OF SIALYLOLIGOSACCHARIDES IN A DAIRY PRODUCTS; OBTAIN ENZYME MIXTURE, INCUBATE WITH MILK, RECOVER SIALYLOLIGOSACCHARIDES | NEOSE TECHNOLOGIES, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20020150995-A1 | Methods for producing sialyloligosaccharides in a dairy source | NEOSE TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | disclosed |
| US-6323008-B1 | CONTACTING .ALPHA.(2,3)TRANS-SIALIDASE WITH DAIRY SOURCE COMPRISING LACTOSE AND SIALIC ACID DONORS TO FORM DAIRY/TRANS-SIALIDASE MIXTURE; INCUBATING TO EFFECT TRANSFER OF SIALIC ACID FROM SIALIC ACID DONORS TO LACTOSE | NEOSE TECHNOLOGIES, INC. | 2001-11-27 | — | — | US | disclosed |
| US-6218161-B1 | DNA ENCODING AN ACTIVE DOMAIN OF N-ACETYLGALACTOSAMINE-ALPHA-2,6-SIALYLTRANSFERASE; FOR RECOMBINANT PRODUCTION | THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1003366-A1 | METHODS FOR PRODUCING SIALYLOLIGOSACCHARIDES IN A DAIRY SOURCE | Neose Technologies, Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999008511-A1 | METHODS FOR PRODUCING SIALYLOLIGOSACCHARIDES IN A DAIRY SOURCE | NEOSE TECHNOLOGIES, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0737745-A1 | NOVEL SUGAR-CHAIN SYNTHETASE AND PROCESS FOR PRODUCING THE SAME | THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH (JP) | 1996-10-16 | — | — | EP | disclosed |
| EP-0586687-A4 | TRANS-SIALIDASE AND METHODS OF USE AND MAKING THEREOF | UNIV NEW YORK (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0586687-A1 | TRANS-SIALIDASE AND METHODS OF USE AND MAKING THEREOF | NEW YORK UNIVERSITY (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1993018787-A1 | TRANS-SIALIDASE AND METHODS OF USE AND MAKING THEREOF | NEW YORK UNIVERSITY (US) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200191-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, FUT5 | ALDH1A1 3182/4885SMN1; SMN2 4767/4885L3MBTL1 1442/4885 |
| US-20160361423-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, FUT5 | ALDH1A1 3182/4885SMN1; SMN2 4767/4885L3MBTL1 1442/4885 |
| US-20170218027-A1 | FUNCTIONAL LIPID CONSTRUCTS | CETP, LCAT, LIPA | ALDH1A1 1782/4885SMN1; SMN2 4732/4885L3MBTL1 1458/4885 |
| US-10919941-B2 | Functional lipid constructs | CETP, LCAT, LIPA | ALDH1A1 1782/4885SMN1; SMN2 4732/4885L3MBTL1 1458/4885 |
| US-20180057518-A1 | SYNTHETIC MEMBRANE ANCHORS | PTDSS2, DDOST, STT3B | ALDH1A1 3805/4885SMN1; SMN2 4788/4885L3MBTL1 149/4885 |
| US-20200123188-A1 | SYNTHETIC MOLECULE CONSTRUCTS | PTDSS2, PTDSS1, UGCG | ALDH1A1 1208/4885SMN1; SMN2 4803/4885L3MBTL1 465/4885 |
| US-20120277172-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, FUT5 | ALDH1A1 3182/4885SMN1; SMN2 4767/4885L3MBTL1 1442/4885 |
| US-10414786-B2 | Synthetic membrane anchors | PTDSS2, DDOST, STT3B | ALDH1A1 3838/4885SMN1; SMN2 4783/4885L3MBTL1 157/4885 |
| US-10858384-B2 | Synthetic molecule constructs | PTDSS2, PTDSS1, UGCG | ALDH1A1 1238/4885SMN1; SMN2 4797/4885L3MBTL1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.